ProQR Therapeutics
PRQR
44 hedge funds and large institutions have $177M invested in ProQR Therapeutics in 2020 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 13 reducing their positions, and 6 closing their positions.
806% more call options, than puts
Call options by funds: $163K | Put options by funds: $18K
31% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 13
10% more capital invested
Capital invested by funds: $161M → $177M (+$16M)
0% more funds holding
Funds holding: 44 → 44 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
5.5% less ownership
Funds ownership: 59.42% → 53.92% (-5.5%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.01M |
| 2 |
RI
RTW Investments
New York
|
+$668K |
| 3 |
JP Morgan Chase
New York
|
+$611K |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
+$607K |
| 5 |
Renaissance Technologies
New York
|
+$587K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.21M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$993K |
| 4 |
Millennium Management
New York
|
-$339K |
| 5 |
CAC
Cowen and Company
New York
|
-$296K |
PRQR Hedge Fund Activity: Q2 2020 in Review
44 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q2 2020, worth a combined $177M — up 9.9% from $161M a quarter earlier.
Fund positioning in PRQR was balanced in Q2 2020: 6 funds opened new positions, 6 closed out, 17 added to existing stakes and 13 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.01M. The largest seller was Fidelity Investments, cutting an estimated $2.21M.
- 44 institutional investors held ProQR Therapeutics (PRQR) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $177M of ProQR Therapeutics stock for Q2 2020, up 9.9% quarter-over-quarter.
- 6 funds opened new ProQR Therapeutics positions in Q2 2020 and 6 closed out, a net change of 0 holders.
- The largest ProQR Therapeutics buyer in Q2 2020 was Morgan Stanley, an estimated $1.01M added.
- The largest ProQR Therapeutics seller in Q2 2020 was Fidelity Investments, an estimated $2.21M sold.
Based on aggregated 13F filings for Q2 2020.